Diagnostics Industry

Found 1,712 articles

• Biocept Announces Pricing of $2.5 Million Registered Direct Offering Priced at Market

  9/21/2018

  Biocept, Inc. today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $2.5 million of its common stock

• 

  As Liquid Biopsies Grow, Who's Going to Pay?

  9/20/2018

  Ilan Danieli, chief executive officer and co-founder of Precipio, a company with a liquid biopsy technology, took time to talk to BioSpace about the company and the economics of liquid biopsies.

• Co-Diagnostics, Inc. to Present at the Fourth Annual Robins Equity Research Roundup

  9/20/2018

  Co-Diagnostics, Inc. announced today that it will be presenting at the Fourth Annual Robins Equity Research Roundup, held September 25 – 26, 2018 near Portland, Oregon.

• MeMed Raises Over $70 Million to Advance Pioneering Point-Of-Care Platform and Immune-Based Test for Distinguishing Bacterial Versus Viral Infections

  9/20/2018

  MeMed today announced the completion of a new round of financing totaling over $70 million, with participation from new and existing investors including Ping An Global Voyager Fund, Foxconn, Caesarea Medical Holdings, Clal Insurance, Phoenix Insurance, OurCrowd, Social Capital, WTI, Horizons Ventures, and high-net-worth executives renowned for early investments in industry-changing companies.

• Anpac Bio & UC Davis Names 2018 ‘Anpac Bio Innovation & Entrepreneurship Scholars’

  9/19/2018

  Fellowships Fund University of California Entrepreneurship

• Cepheid Receives CE-IVD clearance for Xpert HCV VL Fingerstick

  9/19/2018

  Enables Hepatitis C Point-of-Care molecular testing and linkage to care

• ECVAM evaluation of GARDskin rescheduled to an extra scientific committee meeting in spring 2019

  9/19/2018

  SenzaGen has been notified by the European Center for the Validation of Alternative Methods (ECVAM) authority that due to time constrains their scientific committee (ESAC) will not be able to evaluate tests in the category ”Test Guidelines on Health Effects”, to which GARDskin belongs, this year.

• CIRCULOGENE Expands Testing Menu with Somatic BRCA1/2 Blood Testing

  9/19/2018

  ​Enables paired somatic-germline testing, broadens targeted treatment population for breast, ovarian, pancreatic and prostate cancers.

• SenzaGen launches the first in vitro airway allergy test – GARDair – at ESTIV2018

  9/19/2018

  SenzaGen announced today that the company will launch GARDair, the first in vitro test for airway allergies at ESTIV2018, the 20th International Congress on In Vitro Toxicology.

• Resolution Bioscience Earns New York State Approval for Blood-Based Lung Cancer Assay

  9/18/2018

  Resolution Bioscience's ctDx Lung cancer assay identifies actionable mutations in non-small cell lung cancer

• MILabs’ VECTor6 with groundbreaking PET performance awarded Innovation of the Year at the WMIC 2018

  9/18/2018

  MILabs is pleased to announce that its new VECTor6 with Broadband Photon Tomography technique has received the Commercial Innovation Award at the World Molecular Imaging Congress (WMIC) in Seattle September 12th-15th, 2018.

• Avisa Reports on Progress with Biomarker AV BreathTest™ Platform

  9/18/2018

  Avisa Pharma Inc. (“Avisa”) today provided an update on recent progress with its novel rapid, point-of-care breath test – AV BreathTest™.

• Flagship Biosciences Recognized by Frost & Sullivan for Its Industry-leading AI-powered cTA® Platform for Predictive Diagnostics

  9/18/2018

  Based on its recent analysis of the global market for artificial intelligence (AI)-based pathology solutions in immuno-oncology (I-O), Frost & Sullivan recognizes Flagship Biosciences, Inc. (Flagship) with the 2018 Global Technology Innovation Award.

• Qure.ai's qXR Algorithm can ID Abnormal Chest X-rays With Unprecedented Accuracy

  9/18/2018

  Company releases new validation study - the largest-ever with more than 1 million x-rays - that finds its deep learning algorithms can differentiate between normal and abnormal x-rays with unprecedented accuracy

• Agendia and Genecast Biotechnology Partner to Launch MammaPrint® and BluePrint® in China

  9/18/2018

  For the first time, early-stage breast cancer patients and their physicians in China can access clinically validated and prospectively proven tests for breast cancer risk of recurrence and molecular subtyping.

• Prescient Medicine and Metabiomics Partner to Develop New Gastrointestinal Health Tests to Detect Polyps, Prevent Colon Cancer

  9/18/2018

  Innovative new GI health solutions battle colon cancer and gastrointestinal disease.

• 1st Wireless, Handheld, FDA-approved Ultrasound Device to Offer Live Demos at FMX (Family Medicine Experience) 2018, Booth #722

  9/18/2018

  Wireless, app-based technology is positioning the ultrasound to become as ubiquitous as a stethoscope for general practitioners.

• Congenica Announces Market Access Partnership with Digital China Health to Enable Genomic Medicine in the Chinese Market

  9/17/2018

  Partnership will accelerate Congenica’s commercial expansion in the Chinese market

• QIAGEN and NeuMoDx Announce Strategic Partnership to Offer Next-Generation Systems for Fully Integrated Molecular Diagnostic Testing

  9/17/2018

  QIAGEN to launch two Sample to Insight systems in Europe and other markets, NeuMoDx to commercialize in the U.S. / Initial assay menu for infectious diseases and LDTs

• QIAGEN and DiaSorin Launch Automated Testing for Latent TB infection with QuantiFERON-TB Gold Plus Technology on Widely Used LIAISON Platforms

  9/17/2018

  CE-marked workflow enables efficient, high-throughput screening for tuberculosis control efforts in Europe and other markets; introduction in United States expected in 2019 and China in 2020